drugset / Trial / NCT00224783
Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults
Phase 1
Completed
45 enrolled
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The primary objective of the study was to investigate the safety and tolerability of CAIV-T liquid formulation in healthy Japanese male adults.
Timeline
- Start
- 2002-08
- Primary completion
- —
- Completion
- 2002-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | FluMist | Vaccine | 0.2 ml | Intranasal |
Indications
No indication recorded.